Can EMRs (electronic medical records) facilitate gene-based drug prescribing for cardiovascular disease?

Dialogues in Cardiovascular Medicine

Volumn 17, Issue 4, 2012, Pages 293-300

  Denny, Joshua C ^a   Wilke, Russell A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biobank; EMR (electronic medical record); Genomics; Genotyping; Therapy

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; FLUINDOSTATIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DECISION SUPPORT SYSTEM; ELECTRONIC MEDICAL RECORD; GENE THERAPY; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICAL INFORMATION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PRESCRIPTION; RHABDOMYOLYSIS;

EID: 84881539483     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. http://www.ama-assn.org.
2. Lesko LJ, Zineh I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics. 2010;11:507-512.
3. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
4. Wilke RA, Dolan ME. Genetics and variable drug response. JAMA. 2011;306(3):306-307.
5. Roden DM et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84:362-369.
6. McCarty CA et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011;4:13.
7. Ritchie MD, Denny JC, Crawford DC, et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet. 2010;86(4):560-572.
8. Kohane IS. Using electronic health records to drive discovery in disease genomics. Nat Rev Genet. 2011;12:417-428.
9. Baye TM, Wilke RA. Mapping genes that predict treatment outcome in admixed populations. Pharmacogenomics J. 2010;10(6):465-477.
10. Ding K, Bailey KR, Kullo IJ. Genotype-informed estimation of risk of coronary heart disease based on genomewide association data linked to the electronic medical record. BMC Cardiovasc Disord. 2011;11:66.
11. Davis RL. The vaccine adverse event reporting system and vaccine safety research in the genomics era. Vaccine. 2012;30(6):1162-1164.
12. Collins R. What makes UK Biobank special? Lancet. 2012;379:1173-1174.
13. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464-467.
14. www.pharmgkb.org.
15. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92(1):112-117.
16. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2):328-332.
17. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625-629.
18. Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012;13(5):579-594.
19. Link E, Parish S, Armitage J, et al. (SEARCH Collaborative Group). SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359(8):789-799.
20. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609-1609.
21. Wei W, Feng Q, Waitara M, et al. Meaningful use expanded: dose-response curves extracted from EMRs identify genetic predictors of statin potency (ED50) and maximal lipid lowering efficacy (Emax) in a practice-based setting. Submitted and in revision.
22. Delaney JT et al. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther. 2012;91:257-263.
23. Denny JC et al. Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet. 2011;89:529-542.
24. Pulley JM et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther. 2012.doi:10.1038/ clpt.2011.371.
25. Collins F. Opportunities and challenges for the NIH- an interview with Francis Collins. Interview by Robert Steinbrook. N Engl J Med. 2009;361;1321-1323.
26. http://www.mc.vanderbilt.edu
27. Wilke RA et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther. 2011;89:379-386.
28. https://www.medcoresearch.com/community/pharmacogenomics/physicansurvey.
29. Schildcrout JS et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92, 235-242.